{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:40:44Z","timestamp":1792975244913,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Project of Anhui Provincial Scientific Research Plan","award":["NO.2022AH051526"],"award-info":[{"award-number":["NO.2022AH051526"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-20417-8","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:07:55Z","timestamp":1761037675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FAM83A is a prognostic biomarker for lung squamous cell carcinoma and correlated with immunoregulation"],"prefix":"10.1038","volume":"15","author":[{"given":"Cheng","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhe","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangwang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Nian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"3","key":"20417_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"key":"20417_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.omtn.2021.11.013","volume":"27","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Ao, X., Yu, W., Zhang, Y. & Wang, J. Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer. Mol. Ther. Nucleic Acids. 27, 50\u201372 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"20417_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa, C. & Mousa, S. A. Non-small cell lung cancer: current treatment and future advances. Transl. Lung Cancer Res. 5 (3), 288\u2013300 (2016).","journal-title":"Transl. Lung Cancer Res."},{"key":"20417_CR4","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli, C. et al. Non-small-cell lung cancer. Nat. Rev. Dis. Primers. 1, 15009 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"9","key":"20417_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter, A., Veluswamy, R. R. & Wisnivesky, J. P. The global burden of lung cancer: current status and future trends. Nat. Rev. Clin. Oncol. 20 (9), 624\u2013639 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"20417_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","volume":"7","author":"Y Jeong","year":"2017","unstructured":"Jeong, Y. et al. Role of KEAP1\/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. 7 (1), 86\u2013101 (2017).","journal-title":"Cancer Discov."},{"issue":"32","key":"20417_CR7","doi-asserted-by":"publisher","first-page":"52597","DOI":"10.18632\/oncotarget.9544","volume":"7","author":"CA Bartel","year":"2016","unstructured":"Bartel, C. A., Parameswaran, N., Cipriano, R. & Jackson, M. W. FAM83 proteins: fostering new interactions to drive oncogenic signaling and therapeutic resistance. Oncotarget. 7 (32), 52597\u201352612 (2016).","journal-title":"Oncotarget"},{"issue":"8","key":"20417_CR8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1541-7786.MCR-13-0289","volume":"12","author":"R Cipriano","year":"2014","unstructured":"Cipriano, R. et al. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol. Cancer Res. MCR. 12 (8), 1156\u20131165 (2014).","journal-title":"Mol. Cancer Res. MCR"},{"issue":"9","key":"20417_CR9","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1172\/JCI60517","volume":"122","author":"R Cipriano","year":"2012","unstructured":"Cipriano, R. et al. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J. Clin. Investig. 122 (9), 3197\u20133210 (2012).","journal-title":"J. Clin. Investig."},{"issue":"9","key":"20417_CR10","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1172\/JCI60498","volume":"122","author":"SY Lee","year":"2012","unstructured":"Lee, S. Y. et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J. Clin. Investig. 122 (9), 3211\u20133220 (2012).","journal-title":"J. Clin. Investig."},{"issue":"D1","key":"20417_CR11","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53 (D1), D672\u2013d677 (2025).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"20417_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck, F. C., Boffa, D. J., Kim, A. W. & Tanoue, L. T. The eighth edition lung cancer stage classification. Chest. 151 (1), 193\u2013203 (2017).","journal-title":"Chest"},{"key":"20417_CR13","doi-asserted-by":"crossref","unstructured":"Schabath, M. B. & Cote, M. L. Cancer progress and priorities: lung cancer. Cancer Epidemiol. Biomark. Prev. 28(10), 1563\u20131579 (2019).","DOI":"10.1158\/1055-9965.EPI-19-0221"},{"key":"20417_CR14","doi-asserted-by":"publisher","first-page":"680804","DOI":"10.3389\/fonc.2021.680804","volume":"11","author":"R Jin","year":"2021","unstructured":"Jin, R. et al. EGFR-mutated squamous cell lung cancer and its association with outcomes. Front. Oncol. 11, 680804 (2021).","journal-title":"Front. Oncol."},{"issue":"19","key":"20417_CR15","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris, M. G. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (19), 1998\u20132006 (2014).","journal-title":"JAMA"},{"issue":"20","key":"20417_CR16","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"Hirsch, F. R. et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21 (20), 3798\u20133807 (2003).","journal-title":"J. Clin. Oncol."},{"key":"20417_CR17","doi-asserted-by":"crossref","unstructured":"Fulcher, L. J. et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. Sci. Signal. ;11(531). (2018).","DOI":"10.1126\/scisignal.aao2341"},{"key":"20417_CR18","doi-asserted-by":"publisher","first-page":"8767333","DOI":"10.1155\/2022\/8767333","volume":"2022","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Overexpression of FAM83A is associated with poor prognosis of lung adenocarcinoma. J. Oncol. 2022, 8767333 (2022).","journal-title":"J. Oncol."},{"issue":"12","key":"20417_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1593\/neo.05406","volume":"7","author":"Y Li","year":"2005","unstructured":"Li, Y. et al. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia (New York NY). 7 (12), 1073\u20131080 (2005).","journal-title":"Neoplasia (New York NY)"},{"issue":"1","key":"20417_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41392-022-01268-5","volume":"8","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with \u03b2-catenin. Signal. Transduct. Target. Ther. 8 (1), 66 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"5","key":"20417_CR21","doi-asserted-by":"publisher","first-page":"e0176778","DOI":"10.1371\/journal.pone.0176778","volume":"12","author":"CA Bartel","year":"2017","unstructured":"Bartel, C. A. & Jackson, M. W. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss. PLoS One. 12 (5), e0176778 (2017).","journal-title":"PLoS One"},{"key":"20417_CR22","doi-asserted-by":"publisher","first-page":"12623","DOI":"10.2147\/CMAR.S276316","volume":"12","author":"C Liu","year":"2020","unstructured":"Liu, C., Jiang, Y. & Han, B. miR-613 suppresses chemoresistance and stemness in Triple-Negative breast cancer by targeting FAM83A. Cancer Manag. Res. 12, 12623\u201312633 (2020).","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"20417_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40364-022-00353-9","volume":"10","author":"N Marino","year":"2022","unstructured":"Marino, N. et al. FAM83A is a potential biomarker for breast cancer initiation. Biomark. Res. 10 (1), 8 (2022).","journal-title":"Biomark. Res."},{"key":"20417_CR24","doi-asserted-by":"publisher","first-page":"608441","DOI":"10.3389\/fmed.2020.608441","volume":"7","author":"L Rong","year":"2020","unstructured":"Rong, L. et al. FAM83A as a potential biological marker is regulated by miR-206 to promote cervical cancer progression through PI3K\/AKT\/mTOR pathway. Front. Med. 7, 608441 (2020).","journal-title":"Front. Med."},{"issue":"2","key":"20417_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/ijo.2020.5078","volume":"57","author":"J Xu","year":"2020","unstructured":"Xu, J. & Lu, W. FAM83A exerts tumor\u2013suppressive roles in cervical cancer by regulating integrins. Int. J. Oncol. 57 (2), 509\u2013521 (2020).","journal-title":"Int. J. Oncol."},{"issue":"21","key":"20417_CR26","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.7150\/jca.62563","volume":"12","author":"C Lan","year":"2021","unstructured":"Lan, C. et al. FAM83A promotes the proliferative and invasive abilities of cervical cancer cells via Epithelial-Mesenchymal transition and the Wnt signaling pathway. J. Cancer. 12 (21), 6320\u20136329 (2021).","journal-title":"J. Cancer"},{"key":"20417_CR27","doi-asserted-by":"publisher","first-page":"153450","DOI":"10.1016\/j.prp.2021.153450","volume":"222","author":"T Liu","year":"2021","unstructured":"Liu, T. et al. Family with sequence similarity 83 member A promotes tumor cell proliferation and metastasis and predicts poor prognosis in cervical cancer. Pathol. Res. Pract. 222, 153450 (2021).","journal-title":"Pathol. Res. Pract."},{"issue":"3","key":"20417_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/CBM-190520","volume":"26","author":"J Zhang","year":"2019","unstructured":"Zhang, J., Sun, G. & Mei, X. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma. Cancer Biomark. A. 26 (3), 367\u2013373 (2019).","journal-title":"Cancer Biomark. A"},{"issue":"6","key":"20417_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7150\/ijms.33992","volume":"17","author":"H Hu","year":"2020","unstructured":"Hu, H. et al. FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K\/Akt\/mTOR pathways. Int. J. Med. Sci. 17 (6), 807\u2013814 (2020).","journal-title":"Int. J. Med. Sci."},{"key":"20417_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fonc.2020.00180","volume":"10","author":"YW Zheng","year":"2020","unstructured":"Zheng, Y. W. et al. FAM83A promotes lung cancer progression by regulating the Wnt and Hippo signaling pathways and indicates poor prognosis. Front. Oncol. 10, 180 (2020).","journal-title":"Front. Oncol."},{"issue":"5","key":"20417_CR31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1089\/dna.2019.4970","volume":"39","author":"J Yu","year":"2020","unstructured":"Yu, J., Hou, M. & Pei, T. FAM83A is a prognosis signature and potential oncogene of lung adenocarcinoma. DNA Cell Biol. 39 (5), 890\u2013899 (2020).","journal-title":"DNA Cell Biol."},{"issue":"6","key":"20417_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.21037\/tlcr.2019.11.04","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330-5p to promote non-small cell lung cancer progression. Transl. Lung Cancer Res. 8 (6), 862\u2013875 (2019).","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"20417_CR33","doi-asserted-by":"publisher","first-page":"13312","DOI":"10.1080\/21655979.2022.2081457","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao, H. et al. FAM83A antisense RNA 1 (FAM83A-AS1) Silencing impairs cell proliferation and induces autophagy via MET-AMPK\u0251 signaling in lung adenocarcinoma. Bioengineered. 13 (5), 13312\u201313327 (2022).","journal-title":"Bioengineered"},{"issue":"1","key":"20417_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41420-024-02101-4","volume":"10","author":"C Wang","year":"2024","unstructured":"Wang, C., Zhang, J., Wang, H., Chen, R. & Lu, M. Family with sequence similarity 83, member A (FAM83A) inhibits ferroptosis via the Wnt\/\u03b2-catenin pathway in lung squamous cell cancer. Cell. Death Discov. 10 (1), 332 (2024).","journal-title":"Cell. Death Discov."},{"issue":"1","key":"20417_CR35","doi-asserted-by":"publisher","first-page":"17394","DOI":"10.1038\/s41598-024-67686-3","volume":"14","author":"W Yuan","year":"2024","unstructured":"Yuan, W. et al. Screening and identification of MiRNAs negatively regulating FAM83A\/Wnt\/\u03b2-catenin signaling pathway in non-small cell lung cancer. Sci. Rep. 14 (1), 17394 (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"20417_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s12672-024-01109-7","volume":"15","author":"H Liu","year":"2024","unstructured":"Liu, H. et al. Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma. Discover Oncol. 15 (1), 242 (2024).","journal-title":"Discover Oncol."},{"key":"20417_CR37","doi-asserted-by":"publisher","first-page":"1093042","DOI":"10.3389\/fendo.2023.1093042","volume":"14","author":"W Zou","year":"2023","unstructured":"Zou, W. et al. ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer. Front. Endocrinol. 14, 1093042 (2023).","journal-title":"Front. Endocrinol."},{"issue":"5","key":"20417_CR38","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","volume":"179","author":"DP Hollern","year":"2019","unstructured":"Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179 (5), 1191\u20131206e1121 (2019).","journal-title":"Cell"},{"key":"20417_CR39","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.mam.2020.100870","volume":"80","author":"S Sivori","year":"2021","unstructured":"Sivori, S. et al. NK cells and ILCs in tumor immunotherapy. Mol. Aspects Med. 80, 100870 (2021).","journal-title":"Mol. Aspects Med."},{"issue":"1","key":"20417_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","volume":"19","author":"TL Murphy","year":"2022","unstructured":"Murphy, T. L. & Murphy, K. M. Dendritic cells in cancer immunology. Cell Mol. Immunol. 19 (1), 3\u201313 (2022).","journal-title":"Cell Mol. Immunol."},{"issue":"6","key":"20417_CR41","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of Anti-PD-1 therapy. Immunity 50 (6), 1498\u20131512e1495 (2019).","journal-title":"Immunity"},{"key":"20417_CR42","doi-asserted-by":"crossref","unstructured":"Yang, M. et al. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint Blockade in high-grade serous ovarian cancer. J. Immunother. Cancer 9(1). (2021).","DOI":"10.1136\/jitc-2020-001136"},{"key":"20417_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jbo.2018.01.002","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang, Y., Zhang, X., Yang, L., Xue, J. & Hu, G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J. Bone Oncol. 11, 27\u201332 (2018).","journal-title":"J. Bone Oncol."},{"issue":"1","key":"20417_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41392-022-01130-8","volume":"7","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal. Transduct. Target. Ther. 7 (1), 289 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"20417_CR45","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.ebiom.2024.105092","volume":"102","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. A single-cell characterised signature integrating heterogeneity and microenvironment of lung adenocarcinoma for prognostic stratification. EBioMedicine. 102, 105092 (2024).","journal-title":"EBioMedicine"},{"issue":"2","key":"20417_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.7150\/jca.89665","volume":"15","author":"F Zhou","year":"2024","unstructured":"Zhou, F., Liu, Y., Liu, D., Xie, Y. & Zhou, X. Identification of basement membrane-related signatures for estimating prognosis, immune infiltration landscape and drug candidates in pancreatic adenocarcinoma. J. Cancer. 15 (2), 401\u2013417 (2024).","journal-title":"J. Cancer"},{"issue":"9","key":"20417_CR47","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s10147-020-01696-9","volume":"25","author":"F Zhou","year":"2020","unstructured":"Zhou, F., Wang, X., Liu, F., Meng, Q. & Yu, Y. FAM83A drives PD-L1 expression via ERK signaling and FAM83A\/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. Int. J. Clin. Oncol. 25 (9), 1612\u20131623 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"20417_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","volume":"112","author":"R Brody","year":"2017","unstructured":"Brody, R. et al. PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer (Amsterdam Netherlands). 112, 200\u2013215 (2017).","journal-title":"Lung Cancer (Amsterdam Netherlands)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20417-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20417-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:03:54Z","timestamp":1761041034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20417-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20417"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20417-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed on account of the Declaration of Helsinki and approved by the Ethics Committee of Shanghai Pulmonary Hospital Affiliated to Tongji University (NO. K20-044Y) and Ethics Committee of The First Affiliated Hospital of Bengbu Medical University (NO. 2020-146).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"36590"}}